- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00261170
Bupropion for Hospital-Based Smoking Cessation
Studieoversigt
Detaljeret beskrivelse
Two hundred and seventy patients will be enrolled;approximately 135 will be randomized to each study arm over the course of 24 months. Patients will be considered smokers if they have used tobacco products during the week prior to admission and if they have smoked> or = 5 cigarettes /day during the previous year.Smokers will be identified by review of admissions and given a flyer to invite them to join the study. Interested smokers will be screened and asked to fill out a Beck Depression Inventory. Patients with very high Beck Depression Inventory Scores, i.e. > or = 30, will not be enrolled because such individuals may require other treatment. Each patient's physician will be contacted to verify his/her eligibility for the study. Once eligibility has been ascertained, a research associate will visit the patient to obtain informed consent and to enroll them in the study. Study questionnaires and a Fagerstrom test for Nicotine Dependence will be completed and reviewed by a research associate for completeness at the time of enrollment. The associate will put in the prescription for the study drug and request the order for dispensing of the drug. The research pharmacist will randomize the patient to Study Arm 1 or Study Arm 2.
Subjects randomized to Study Arm 1 will receive a standard 7-week course of sustained release bupropion (150 mg/day for the first 3 days, then 150mg BID), a self-help booklet, counseling on smoking cessation strategies, and follow-up phone counseling during the first 3 months after randomization. Study Arm 2 participants will receive the same intervention as Study Arm 1, but will receive placebo instead of active bupropion therapy. Both study groups will complete study questionnaires regarding their medical and smoking history and will be followed one week after their hospital discharge to record their blood pressure and to monitor possible side effects.
Since quit rates tend to decline over time, relapse prevention approaches will be included in both study arms. Marlatt's theory of relapse, an extension of Bandura's social learning model, will be used to augment the quitter's perception of self-efficacy. Participants will be trained to resist and cope with the temptations and stresses likely to be encountered after discharge from the hospital. Behavioral self-management techniques to counter known relapse-triggers such as stress, the presence of other smokers, alcohol use and depression will be discussed during follow-up counseling calls.
We will measure saliva cotinine in all participants who give a history of smoking abstinence at the end of treatment and at 6 months. Cotinine levels of > or + 15 ng/mL will be considered evidence of current tobacco use. Participants who are self-reported quitters, but have failed to provide a saliva sample will be considered as smokers unless verification from a spouse or significant other can be obtained. Participants who have died will be analyzed as smokers or quitters based on prior self-report, information in medical records, or interviews with next-of-kin. Others will be censored (i.e. excluded from the analysis). All cotinine samples will be assayed at the University of California, San Francisco,laboratory of Dr. Neal Benowitz.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
California
-
San Francisco, California, Forenede Stater, 94121
- Veterans Affairs Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- currently smoking - use of tobacco products during the week prior to hospital admission and having smoked at least 5 cigarettes /day during the past year
- eligibility to receive medical care in a VA hospital
- hospitalization for at least 48 hours to provide sufficient time to identify, screen, enroll and counsel participants
- willingness to participate and give informed consent
Exclusion Criteria:
- hospitalization for acute CHD syndromes
- contraindications to the use of bupropion
- family history of seizure disorder, history of severe head trauma, predisposition to seizures
- unstable psychiatric disorder
- pregnancy, lactation
- current alcohol (defined as greater than 3 drinks/day) or drug abuse (defined as current/within last 3 months use of narcotics, heroin, cocaine, amphetamines)
- current untreated depression (BDI score > or = 30)
- terminal illness
- inability to be contacted by phone
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: 1
bupropion and behavioral counseling
|
150 mg daily for the first 3 days, then 150 mg twice daily for 7 weeks
Andre navne:
|
Placebo komparator: 2
placebo medication
|
1 pill daily for the first 3 days, then one pill twice daily for 7 weeks
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Smoking status at 6 months after enrollment
Tidsramme: 6 months
|
6 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
smoking status at end of treatment
Tidsramme: 7 weeks
|
7 weeks
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Joel A Simon, MD, MPH, University of California, San Francisco
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Lægemidlers fysiologiske virkninger
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Psykotropiske stoffer
- Neurotransmitter optagelseshæmmere
- Membrantransportmodulatorer
- Antidepressive midler
- Dopaminmidler
- Cytokrom P-450 enzymhæmmere
- Antidepressive midler, anden generation
- Cytokrom P-450 CYP2D6-hæmmere
- Dopaminoptagelseshæmmere
- Bupropion
Andre undersøgelses-id-numre
- 12RT-0148
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med bupropion
-
Orexigen Therapeutics, IncAfsluttet
-
University of Rochester NCORP Research BaseNational Cancer Institute (NCI)RekrutteringBlive diagnosticeret med kræft og have gennemført systemisk terapiForenede Stater
-
Altschuler, Eric, M.D.GlaxoSmithKlineAfsluttet
-
Mayo ClinicNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Afsluttet
-
Alembic Pharmaceuticals Ltd.Afsluttet
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloAfsluttetRygestop | Genetisk dispositionBrasilien
-
NRG OncologyNational Cancer Institute (NCI)AfsluttetBrystkarcinom | Cervikal karcinom | Vaginalt karcinom | Ovariekarcinom | Kræft i livmoderen | Vulvar karcinom | PostmenopausalForenede Stater
-
University of Wisconsin, MadisonNational Institute on Drug Abuse (NIDA); National Cancer Institute (NCI)Afsluttet
-
University of Wisconsin, MadisonNational Institutes of Health (NIH)Afsluttet
-
GlaxoSmithKlineAfsluttet